secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001576280-26-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q1 revenue rises 48% to $301.7 million, boosts 2026 guidance
----------------------------------------------------------------------------

- Revenue increased 48% to $301.7M driven by Oncology revenue growth of 36% and Screening revenue surge to $41.6M.
- Net loss per share widened to $0.85 from $0.77; non-GAAP net loss per share improved to $0.45 from $0.49.
- Raised 2026 revenue guidance to $1.30-$1.32B (32-34% growth), up from prior $1.25-$1.28B; Oncology volume growth expected >35%.
- Shield screening tests reached 44,000 in Q1; 2026 Shield volume guidance raised to 230,000-245,000 tests.
- Q1 adjusted EBITDA loss of $58.9M relatively flat; free cash flow burn $71.2M; cash position $1.2B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628026000024/0001576280-26-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628026000024/gh-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001576280-26-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer